Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05919563 · ClinicalTrials.gov registry record

LTFU Study of Subjects Who Received GRNOPC1

A clinical trial of Spinal Cord Injuries, sponsored by Lineage Cell Therapeutics.

Active
Registry status
5
Enrollment target
3
Study locations

NCT05919563 is a study of Spinal Cord Injuries that is active but no longer recruiting, run by Lineage Cell Therapeutics. The registered enrollment target is 5 participants, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05919563, a study of Spinal Cord Injuries, is active but no longer recruiting, sponsored by Lineage Cell Therapeutics.

ACTIVE NOT RECRUITING
Registry status
5 participants
Enrollment target
3
Study locations

Study Summary

This is a LTFU study for thoracic SCI subjects that were administered GRNOPC1 cells in the main study CP35A007.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Magnetic Resonance Imaging (MRI)

Study Locations (3)

California

  • Stanford University - Palo Alto

Georgia

  • Shepherd Center - Atlanta

Illinois

  • Northwestern Medical Group - Evanston

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2011-10-06
Est. Completion 2026-12-12

Sponsor

Lineage Cell Therapeutics

5 total trials

What the Registry Record Tells You About NCT05919563

The ClinicalTrials.gov registry entry for NCT05919563 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (92% lower). The listed sponsor is Lineage Cell Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Spinal Cord Injuries appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Resonance Imaging (MRI) is the first listed.

NCT05919563 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT05919563 about?

NCT05919563 is a clinical study titled "LTFU Study of Subjects Who Received GRNOPC1". This is a LTFU study for thoracic SCI subjects that were administered GRNOPC1 cells in the main study CP35A007.

What is the current status of trial NCT05919563?

This trial is currently active not recruiting. The enrollment target is 5 participants. The study started on 2011-10-06. Estimated completion is 2026-12-12.

What conditions does trial NCT05919563 study?

This clinical trial studies the following conditions: Spinal Cord Injuries.

What interventions are being tested in trial NCT05919563?

The interventions under investigation include: Magnetic Resonance Imaging (MRI) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05919563?

This trial is sponsored by Lineage Cell Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05919563 being conducted?

This trial has 3 study locations across California, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.